Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.
Dermatol Ther. 2020 May 01;:e13475
Authors: Damiani G, Pacifico A, Bragazzi NL, Malagoli P
During COVID-19 outbreak there are discordant opinion towards the impact on biologics in psoriatic patients. Thus we performed a single center case-control study in Lombardia, the Italian region with the higher number of COVID-19 confirmed cases. We enrolled 1193 PsO patients treated with biologics and small molecules and we used the entire Lombardia population as controls. Notably, 17 PsO patients COVID-19 confirmed were quarantined at home and 5 hospitalized, no PsO patients were admitted to intensive care unit (ICU) or died. With respect to the general population of Lombardy, patients on biologics were at higher risk to be symptomatic for COVID-19 (OR 3.43 [95%CI 2.25-5.73], P < 0.0001), to be self-quarantined at home (OR 9.05 [95%CI 5.61-14.61], P < 0.0001) and hospitalized (OR 3.59 [95%CI 1.49-8.63], P = 0.0044) however not increased risk of ICU admission or death were found. PsO Patients on biologics should be carefully monitored with telemedicine during COVID-19 outbreak and early treated at home to limit hospital overwhelm. This article is protected by copyright. All rights reserved.
PMID: 32356577 [PubMed - as supplied by publisher]